GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » Loans Receivable

Eisai Co (TSE:4523) Loans Receivable : 円0 Mil (As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Eisai Co Loans Receivable?

Eisai Co's Loans Receivable for the quarter that ended in Dec. 2023 was 円0 Mil.


Eisai Co Loans Receivable Historical Data

The historical data trend for Eisai Co's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Loans Receivable Chart

Eisai Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eisai Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Eisai Co Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Eisai Co Loans Receivable Related Terms

Thank you for viewing the detailed overview of Eisai Co's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (TSE:4523) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines